SOLICITATION NOTICE
68 -- Generation of Custom Rabbit Monoclonal Antibody directed against Human Fibroblast Growth Factor Receptor 4
- Notice Date
- 6/8/2009
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90101-NG
- Archive Date
- 7/7/2009
- Point of Contact
- Malinda L Holdcraft, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
holdcram@exchange.nih.gov, cr214i@nih.gov
(holdcram@exchange.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR) plans to procure on a sole source basis for the Generation of Custom Rabbit Monoclonal Antibody directed against Human Fibroblast Growth Factor Receptor 4 (FGFR4), with Epitomics, Inc.; 863 Mitten Road; Suite 103; Burlingame, CA 94010-1303. The supplies and services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106. The North American Industry Classification System code is 325413 and the business size standard is 500 employees. Only one award shall be made as a result of this solicitation. Period of Performance shall be from date of award through 12 months. The purpose of the requirement is to develop high affinity rabbit mAb to neutralize FGFR4 which might be exploited as adjuvant therapy for metastatic disease. Fibroblast Growth Factor Receptor 4 is over-expressed in rhabdomyosarcoma and the expression is correlated with advanced disease and poorer survival. The NCI requires Rabbit Monoclonal Hybridomas (antibodies) generated through fusion of spleen cells of immunized rabbits with Rabbit Plasmacytoma cells (240E or their derivatives). The antibodies will be directed against specific proteins relevant to Cancer research. Epitomics is uniquely qualified to design, develop and deliver the antibodies as part of the continued research studies within the NCI. Epitomics is the only source known to the NCI that has an exclusive license for the 240E cell line that was developed by Katherine Knight at Loyola University. The founders of Epitomics cloned the cells and isolated derivatives that are more stable and more productive than the parental cells. These improved cells are used in their protocols for development of rabbit monoclonal antibodies. In addition, Epitomics owns the patent for the Rabbit Plasmacytoma fusion partner required to generate hybridomas from rabbit spleen cells. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Contractor shall provide one (1) original and one (1) copy of the capability statement. Capability statements must be received in the contracting office by 11:00 AM ET June 22, 2009. All questions must be in writing and can be faxed or emailed to the following: Malinda Holdcraft, Contract Specialist via electronic mail at holdcram@exchange.nih.gov or fax 301-402-4513. It is the contractors’ responsibility to ensure all questions have been received in the contracting office. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certifications in the Central Contractor Registration (CCR) and the Online Representations and Certification Application (ORCA). Please reference NCI-90101-NG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90101-NG/listing.html)
- Record
- SN01838948-W 20090610/090608235235-c27f6c85c6172dc1c12bb07a2330b2c0 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |